ストックスクリーナーアプリを入手
12.09
11.12%
1.21
アフターアワーズ：
11.50
-0.59
-4.88%
Adlai Nortye Ltd Adr (ANL) 最新ニュース
Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab - GlobeNewswire Inc.
ADARx Pharmaceuticals, Inc. (ADRX) Stock Price & News - Syfe
Adlai Nortye director Ji Ping sells $83,150 in shares - Investing.com
Adlai Nortye director Ji Ping sells $83,150 in shares By Investing.com - Investing.com Nigeria
Adlai Nortye (NASDAQ: ANL) director lines up ADS sale - Stock Titan
Adlai Nortye (NASDAQ: ANL) readies new offerings as holders plan a large ADS resale - Stock Titan
Jefferies initiates Adlai Nortye stock with buy rating on drug potential - Investing.com Australia
Jefferies initiates Adlai Nortye stock with buy rating on drug potential - Investing.com Canada
Jefferies initiates Adlai Nortye stock with buy rating on drug potential - investing.com
Adlai Nortye (NASDAQ: ANL) Initiates Global Phase I Trial for AN4035 with Phase Ia Data Expected in Late 2027 - Kalkine Media
Adlai Nortye Launches Global Phase I Trial of First-in-Class RAS-Targeting ADC AN4035 - TipRanks
Lucid Capital Markets initiates Adlai Nortye stock with buy rating By Investing.com - Investing.com Nigeria
Lucid Capital Markets initiates Adlai Nortye stock with buy rating - investing.com
Lucid Capital Markets initiates Adlai Nortye stock with buy rating By Investing.com - Investing.com Canada
Adlai Nortye doses first patient in AN4035 cancer trial By Investing.com - Investing.com Canada
Lucid Capital Markets initiates Adlai Nortye stock with buy rating By Investing.com - Investing.com UK
Adlai Nortye doses first patient in AN4035 cancer trial By Investing.com - Investing.com India
Adlai Nortye doses first patient in AN4035 cancer trial - Investing.com
Adlai Nortye doses first patient in AN4035 cancer trial By Investing.com - Investing.com UK
Adlai Nortye CFO Ye Xiaofeng Reports Sale of 11,667 ADS in Two Open-Market Transactions - Kalkine Media
Adlai Nortye Calls September Extraordinary Meeting to Authorize Major Share Issuance and Board Changes - TipRanks
Adlai Nortye (ANL) sets vote on new share authorization - Stock Titan
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? - Eastern Progress
Adlai Nortye Redomiciles to Singapore and Updates Nasdaq Identity - TipRanks
Adlai Nortye (Nasdaq: ANL) shifts to Singapore with super-voting shares - Stock Titan
Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High? - Yahoo Finance
Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High? - Zacks Investment Research
HC Wainwright Increases Earnings Estimates for Adlai Nortye - MarketBeat
Adlai Nortye (NASDAQ:ANL) Stock Price Up 6.2%Still a Buy? - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Acurx Pharmaceuticals (ACXP) - The Globe and Mail
Adlai Nortye Boosts Cash Reserves and Advances RAS-Focused Oncology Pipeline in First Half of 2026 - TipRanks
Adlai Nortye (ANL) Earnings Date and Reports 2026 $ANL - MarketBeat
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Adlai Nortye (ANL) Sheds 0.75% to $13.18 as Biotech ADR Holds Above Key SupportMoney Flow Index - dars.gov.et
Adlai Nortye (ANL) Sheds 0.75% to $13.18 as Biotech ADR Holds Above Key SupportComposite Profile - siam.in
Adlai Nortye (ANL) Sheds 0.75% to $13.18 as Biotech ADR Holds Above Key SupportComposite Profile - siam.in
Adlai Nortye (ANL) Sheds 0.75% to $13.18 as Biotech ADR Holds Above Key SupportTechnical Analysis Picks - dars.gov.et
Adlai Nortye Initiated at Buy as First-in-Class RASiCA ADC Enters Clinic; $20 Price Target Reiterated - TipRanks
Adlai Nortye receives approval to begin trial in Australia - Investing.com
Adlai Nortye Wins Australian Clearance to Launch First-in-Class Pan-RAS(ON) ADC Trial - TipRanks
ADAR1 Capital Management LLC Makes New $816,000 Investment in Adlai Nortye Ltd. Sponsored ADR $ANL - MarketBeat
Affinity Asset Advisors LLC Takes Position in Adlai Nortye Ltd. Sponsored ADR $ANL - MarketBeat
Adlai Nortye Ltd. Sponsored ADR (ANL) Receives a Buy from Cantor Fitzgerald - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Adlai Nortye Begins Weekly Dosing Arm in Global Phase 1 Trial of RAS Inhibitor AN9025 - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: Fractyl Health, Inc. (GUTS), AbbVie (ABBV) - The Globe and Mail
Adlai Nortye: Buy Rating Reaffirmed as Dual-Arm AN9025 Strategy Advances; $20 Price Target Maintained - TipRanks
Adlai Nortye doses first patient in weekly trial arm of AN9025 - Investing.com
Adlai Nortye doses first patient in weekly trial arm of AN9025 - Investing.com Nigeria
Adlai Nortye doses first patient in weekly trial arm of AN9025 - Investing.com Canada
3.36%
0.16%
大文字化:
|
ボリューム (24 時間):